25
January 2024
IXICO plc
("IXICO" or the
"Company")
Results of
AGM
IXICO plc (AIM: IXI), the medical imaging
advanced analytics company delivering insights in
neuroscience announces that all resolutions
put forward to its Annual General Meeting held earlier today were
duly passed and the votes cast were as follows:
|
|
RESOLUTION
|
VOTES
FOR
|
%
|
VOTES
AGAINST
|
%
|
VOTES
TOTAL
|
% ISC VOTED
|
VOTES
WITHHELD
|
|
1
|
Reports and Accounts
|
20,820,635
|
99.92%
|
16,913
|
0.08%
|
20,837,548
|
43.10
|
7,409
|
|
2a
|
Re-election of Mark Warne
|
20,811,026
|
99.87%
|
26,948
|
0.13%
|
20,837,974
|
43.10
|
6,983
|
|
2b
|
Election of Dipti Amin
|
20,814,152
|
99.92%
|
17,113
|
0.08%
|
20,831,265
|
43.08
|
13,692
|
|
3
|
Appointment of Moore Kingston Smith Auditors
|
20,819,713
|
99.88%
|
24,122
|
0.12%
|
20,843,835
|
43.11
|
1,122
|
|
4
|
Allotment of Securities
|
20,819,913
|
99.89%
|
23,822
|
0.11%
|
20,843,735
|
43.11
|
1,222
|
|
5
|
* Disapply Pre-Emption
Provisions
|
20,800,863
|
99.80%
|
42,572
|
0.20%
|
20,843,435
|
43.11
|
1,522
|
* Special
Resolution
Please note that a 'vote withheld'
is not a vote under English Law and is not counted in the
calculation
of the proportion of the votes 'for'
and 'against' a resolution.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser
and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More
information is available on www.IXICO.com and
follow us on Twitter @IXICOnews